Literature DB >> 31494844

Age-related burden and characteristics of embolic stroke of undetermined source in the real world clinical practice.

Elisa Grifoni1, Davide Giglio1, Giulia Guazzini1, Eleonora Cosentino1, Ester Latini1, Alessandro Dei1, Attilio Del Rosso2, Vincenzo Guarnaccia2, Mariella Baldini3, Maria Letizia Bartolozzi3, Pietro Martinucci4, Francesca Sani4, Antonio Giordano1, Francesca Dainelli1, Francesca Maggi1, Chiara Giulietti1, Mario Romagnoli1, Stefano Cinotti1, Elena Schipani1, Giuseppe Salvatore Murgida1, Stefania Di Martino1, Andrea Cozzi1, Adele Carli Ballola1, Debora Dacomo1, Debora Valori2, Luca Masotti5.   

Abstract

Few data are available on age-related burden and characteristics of embolic stroke of undetermined source (ESUS) in the real world clinical practice. The aim of our study was to provide information about it. We retrospectively analyzed data of patients consecutively admitted to our Stroke Unit along 1 year (2017, November 1st-2018, October 31st). The etiology of ischemic stroke was defined at hospital discharge; ESUS was considered as a subset of cryptogenic stroke, and defined according to the 2014 international criteria. In the analyzed period, 306 patients, 52.3% females, mean age ± SD 77.9 ± 11.9 years, were discharged with diagnosis of ischemic stroke. Ischemic strokes of cardioembolic and lacunar origin were the most frequent subtypes: 30.1% and 29.4%, respectively. Cardioembolic strokes were particularly frequent in patients ≥ 75 years, and almost always associated with atrial fibrillation. Overall, in 80 patients (26.1%) the etiology of stroke was undetermined; in 25 (8.2%) it remained undefined because of death or severe comorbidity, making further diagnostic work-up not worthy. Cryptogenic stroke occurred in 55 patients (18%), and ESUS criteria were satisfied in 39 of them (12.7%). According to age, cryptogenic stroke was diagnosed in 21.1% (21.1% ESUS) of patients < 65 years, 24.2% (19.4% ESUS) of patients aged 65-74 years, 15.5% (9.2% ESUS) of patients ≥ 75 years. After diagnostic work-up, patent foramen ovale was most commonly associated with ESUS (17.9%), especially in patients < 65 years (62.5%); covert paroxysmal atrial fibrillation was detected in 10.5% of ESUS patients ≥ 75 years. In the real world clinical practice, the frequency of ischemic strokes of undetermined etiology, and of those satisfying ESUS criteria, is not negligible, especially in younger patients. A thorough diagnostic work-up, with an age-specific approach, is therefore necessary and of the utmost importance for the identification of stroke etiology, in order to optimize secondary stroke prevention strategies.

Entities:  

Keywords:  Atrial fibrillation; Cryptogenic stroke; Embolic stroke of undetermined source (ESUS); Ischemic stroke etiology; Patent foramen ovale

Mesh:

Year:  2020        PMID: 31494844     DOI: 10.1007/s11239-019-01951-5

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  25 in total

Review 1.  Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update.

Authors:  Robert G Hart; Luciana Catanese; Kanjana S Perera; George Ntaios; Stuart J Connolly
Journal:  Stroke       Date:  2017-03-06       Impact factor: 7.914

2.  Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices.

Authors:  David T Martin; Malcolm M Bersohn; Albert L Waldo; Mark S Wathen; Wassim K Choucair; Gregory Y H Lip; John Ip; Richard Holcomb; Joseph G Akar; Jonathan L Halperin
Journal:  Eur Heart J       Date:  2015-04-23       Impact factor: 29.983

Review 3.  Classifying Ischemic Stroke, from TOAST to CISS.

Authors:  Pei-Hao Chen; Shan Gao; Yong-Jun Wang; An-Ding Xu; Yan-Sheng Li; David Wang
Journal:  CNS Neurosci Ther       Date:  2012-01-24       Impact factor: 5.243

4.  Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design.

Authors:  Tobias Geisler; Sven Poli; Christoph Meisner; Juergen Schreieck; Christine S Zuern; Thomas Nägele; Johannes Brachmann; Werner Jung; Georg Gahn; Elisabeth Schmid; Hansjörg Bäezner; Timea Keller; Gabor C Petzold; Jan-Wilko Schrickel; Jan Liman; Rolf Wachter; Frauke Schön; Martin Schabet; Alfred Lindner; Albert C Ludolph; Hubert Kimmig; Sebastian Jander; Uwe Schlegel; Meinrad Gawaz; Ulf Ziemann
Journal:  Int J Stroke       Date:  2016-11-23       Impact factor: 5.266

5.  Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.

Authors:  Hans-Christoph Diener; Ralph L Sacco; J Donald Easton; Christopher B Granger; Richard A Bernstein; Shinichiro Uchiyama; Jörg Kreuzer; Lisa Cronin; Daniel Cotton; Claudia Grauer; Martina Brueckmann; Marina Chernyatina; Geoffrey Donnan; José M Ferro; Martin Grond; Bernd Kallmünzer; Jerzy Krupinski; Byung-Chul Lee; Robin Lemmens; Jaime Masjuan; Miroslav Odinak; Jeffrey L Saver; Peter D Schellinger; Danilo Toni; Kazunori Toyoda
Journal:  N Engl J Med       Date:  2019-05-16       Impact factor: 91.245

6.  The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study.

Authors:  Taya V Glotzer; Emile G Daoud; D George Wyse; Daniel E Singer; Michael D Ezekowitz; Christopher Hilker; Clayton Miller; Dongfeng Qi; Paul D Ziegler
Journal:  Circ Arrhythm Electrophysiol       Date:  2009-08-04

7.  Warfarin-Aspirin Recurrent Stroke Study (WARSS) trial: is warfarin really a reasonable therapeutic alternative to aspirin for preventing recurrent noncardioembolic ischemic stroke?

Authors:  Graeme J Hankey
Journal:  Stroke       Date:  2002-06       Impact factor: 7.914

8.  Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry.

Authors:  Kanjana S Perera; Thomas Vanassche; Jackie Bosch; Mohana Giruparajah; Balakumar Swaminathan; Katie R Mattina; Scott D Berkowitz; Antonio Arauz; Martin J O'Donnell; Sebastian F Ameriso; Graeme J Hankey; Byung-Woo Yoon; Philippa Lavallee; Luis Cunha; Nikolay Shamalov; Raf Brouns; Rubens J Gagliardi; Scott E Kasner; Alessio Pieroni; Philipp Vermehren; Kazuo Kitagawa; Yongjun Wang; Keith Muir; Jonathan Coutinho; Ildiko Vastagh; Stuart J Connolly; Robert G Hart
Journal:  Int J Stroke       Date:  2016-04-11       Impact factor: 5.266

9.  Embolic strokes of undetermined source: the case for a new clinical construct.

Authors:  Robert G Hart; Hans-Christoph Diener; Shelagh B Coutts; J Donald Easton; Christopher B Granger; Martin J O'Donnell; Ralph L Sacco; Stuart J Connolly
Journal:  Lancet Neurol       Date:  2014-04       Impact factor: 44.182

10.  Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT.

Authors:  Isabelle C Van Gelder; Jeff S Healey; Harry J G M Crijns; Jia Wang; Stefan H Hohnloser; Michael R Gold; Alessandro Capucci; Chu-Pak Lau; Carlos A Morillo; Anne H Hobbelt; Michiel Rienstra; Stuart J Connolly
Journal:  Eur Heart J       Date:  2017-05-01       Impact factor: 29.983

View more
  1 in total

Review 1.  Review and update of the concept of embolic stroke of undetermined source.

Authors:  Hans-Christoph Diener; J Donald Easton; Robert G Hart; Scott Kasner; Hooman Kamel; George Ntaios
Journal:  Nat Rev Neurol       Date:  2022-05-10       Impact factor: 44.711

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.